Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy plus PD-1 inhibitor, bevacizumab, and TAS-102 for metastatic colorectal cancer after second-line failure
ChiCTR2400095023Phase 2Not yet recruiting
- Sponsor
- Sichuan Mianyang 404 Hospital
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Sichuan Mianyang 404 Hospital. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400095023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400095023.